Laninamivir as good as Tamiflu in Asian Phase III trial
10 August 2009
Ian Haydock
Top line results from a Phase III comparative study have shown
Daiichi Sankyo/
Biota Holdings' inhaled long-acting neuraminidase inhibitor laninamivir (CS-8958) was non-inferior to Tamiflu in terms of time to resolution of flu symptoms in adult and paediatric patients.
The news lifted Daiichi...
Please Login to read the full article.
10 August 2009
Ian Haydock
The news lifted Daiichi...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Phase II success in HCC for c-MET inhibitor as monotherapy
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
- Kyowa Kirin takes tivantinib into Asian Phase III trial for lung cancer
- US Capitol Capsule: Use of mind-altering medicines in children, elderly under fire
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
